| Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response … |
2023-5-11 |
2023-6-15 |
|
| Synthetic nanocarriers comprising an immunosuppressant in combination with high … |
2023-3-24 |
2023-9-28 |
|
| Controlled release of immunosuppresant from synthetic nanocarrier |
2023-3-08 |
2023-6-20 |
|
| Immunosuppressant in combination with high affinity il-2 receptor agonists and … |
2023-3-08 |
2023-9-14 |
|
| Immunosuppressants in combination with anti-igm agents and related dosing |
2023-3-08 |
2023-9-14 |
|
| Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
2023-2-13 |
2023-5-23 |
|
| High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
2023-1-09 |
2023-8-24 |
|
| Multiple dosing with viral vectors |
2022-11-14 |
2023-5-19 |
|
| Viral vector dosing protocols |
2022-10-12 |
2023-5-04 |
|
| Methods and compositions for attenuating anti-viral transfer vector igm … |
2022-10-12 |
2023-4-20 |
|
| Methods and compositions for inducing autophagy |
2022-10-12 |
2022-12-01 |
|
| Dosing combinations for reducing undesired humoral immune responses |
2022-9-15 |
2022-10-06 |
|
| Methods and compositions related to synthetic nanocarriers with rapamycin in … |
2022-9-01 |
2022-11-18 |
|
| Methods and compositions related to combined treatment with anti-inflammatories … |
2022-8-30 |
2023-4-06 |
|
| Osmotic mediated release synthetic nanocarriers |
2022-7-28 |
2023-5-04 |
|
| Formulations and doses of pegylated uricase |
2022-5-04 |
2022-7-01 |
|
| Methods and compositions for treating liver diseases and disorders |
2022-4-20 |
2022-6-01 |
|
| Synthetic nanocarriers comprising an immunosuppressant in combination with high … |
2022-4-08 |
2022-10-13 |
|
| Methods and compositions for attenuating gene editing anti-viral transfer … |
2022-2-27 |
2022-3-24 |
|
| Repeated administration of non-immunosuppressive antigen-specific … |
2022-1-31 |
2022-5-24 |
|
| Formulations and doses of pegylated uricase |
2022-1-27 |
2022-5-09 |
|
| Viral vector dosing protocols |
2022-1-05 |
2023-7-13 |
|
| Methods and compositions for attenuated anti-viral transfer vector immune … |
2021-11-22 |
2022-1-01 |
|
| Compositions for reducing immune responses to immunoglobulins proteases |
2021-11-04 |
2023-8-08 |
|
| Methods for treatment of subjects with preexisting immunity to viral transfer … |
2021-10-27 |
2021-12-01 |
|
| METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOVEHICLES |
2021-3-11 |
2022-10-25 |
|
| Methods and compositions using synthetic nanocarriers comprising … |
2021-2-26 |
2022-10-01 |
|
| Methods and compositions of mma constructs and vectors |
2021-1-13 |
2021-3-01 |
|
| Methods and compositions of otc constructs and vectors |
2021-1-13 |
2021-3-01 |
|
| Formulations and doses of pegylated uricase |
2020-6-04 |
2020-12-10 |
|
| Methods and compositions for attenuating anti-viral transfer vector igm … |
2020-4-06 |
2020-5-31 |
|
| Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) … |
2020-3-29 |
2020-5-31 |
|
| Nanocarriers possessing components with different rates of release |
2020-1-27 |
2020-12-17 |
|
| Synthetic nanocarrier combination vaccines |
2019-9-24 |
2019-11-28 |
|
| Compositions that induce t cell help |
2017-10-15 |
2017-12-31 |
|
| Recombinant immunotoxins for use in the treatment of cancer |
2017-9-27 |
2018-4-05 |
|
| Immunostimulatory oligonucleotides |
2017-8-30 |
2018-2-15 |
|
| Polyester polymer matrices for the delivery of allergens |
2017-8-24 |
2018-3-01 |
|
| Immunonanotherapeutics providing a th1-biased response |
2017-6-22 |
2017-12-07 |
|
| Methods and compositions for treatment with synthetic nanocarriers and immune … |
2015-6-25 |
2015-12-30 |
|
| Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
2015-6-17 |
2015-12-17 |
|
| Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic … |
2015-2-03 |
2016-8-04 |
|
| Nanovecteurs synthétiques comprenant un immunosuppresseur en association avec … |
2023-3-24 |
2023-9-28 |
|